Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SORBITRATE vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Prophylaxis of angina pectoris (to reduce frequency and severity of anginal attacks),Chronic management of angina pectoris (as part of long-term therapy),Off-label: Congestive heart failure (adjunctive therapy to reduce preload and afterload),Off-label: Esophageal spasm (symptomatic relief)
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Terminal elimination half-life: 5–6 hours. Clinical context: supports dosing every 6–8 hours; requires nitrate-free interval to prevent tolerance.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Isosorbide dinitrate undergoes extensive first-pass metabolism in the liver via glutathione-dependent organic nitrate reductase (likely mediated by mitochondrial aldehyde dehydrogenase, ALDH2) to active metabolites isosorbide-2-mononitrate and isosorbide-5-mononitrate, with the latter being the major active metabolite. These metabolites are further glucuronidated and excreted renally.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Renal: ~20% unchanged; remainder as metabolites (isosorbide-2-mononitrate, isosorbide-5-mononitrate). Biliary/fecal: negligible.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
~28% bound to albumin.
Approximately 30% bound to plasma proteins, primarily albumin.
Vd: 1.5–3.5 L/kg. Clinical meaning: extensive tissue distribution, high uptake in vascular smooth muscle.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Sublingual: ~40–60% (bypasses first-pass metabolism). Oral: ~10–20% (extensive first-pass hepatic metabolism).
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dose adjustment required. GFR <10 m L/min: limited data, consider reduced dose.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% or extend dosing interval.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Not recommended for children <18 years due to lack of safety data.
Safety and efficacy not established; no standard dosing recommendations.
Start at lower end of dosing range (e.g., sublingual 2.5 mg, oral 10 mg twice daily) due to increased sensitivity and risk of hypotension.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
No FDA boxed warning.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension: May cause severe hypotension, especially upon standing (orthostatic hypotension). Correct hypovolemia before use.,Tolerance: Continuous use may lead to development of tolerance; a daily nitrate-free interval (10-12 hours) is recommended to maintain efficacy.,Headache: Common, often dose-limiting; may be severe initially but decreases with continued use.,Worsening angina: Abrupt discontinuation may precipitate angina; taper gradually.,Hypertrophic cardiomyopathy: Use with caution in patients with hypertrophic obstructive cardiomyopathy as vasodilation may worsen outflow obstruction.,Increased intracranial pressure: Use with caution in patients with increased intracranial pressure (e.g., head trauma, cerebral hemorrhage).
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypersensitivity to isosorbide dinitrate or any component of the formulation,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe hypotension (systolic BP < 90 mm Hg),Cardiogenic shock (unless used to maintain coronary perfusion pressure with inotropic support),Obstructive cardiomyopathy (relative contraindication),Increased intracranial pressure (relative contraindication)
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
No significant food interactions, but high-fat meals may delay absorption. Avoid excessive alcohol, which can cause additive vasodilation and hypotension.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a potential risk of fetal hypoxia, especially during the second and third trimesters. Use only if clearly needed.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
It is not known if isosorbide dinitrate is excreted in human milk. The M/P ratio is unknown. Because many drugs are excreted in milk, caution should be exercised when administered to a nursing woman.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
No specific dose adjustments are recommended, but due to increased plasma volume and altered hemodynamics in pregnancy, lower starting doses may be considered, titrating to clinical response. Monitor for hypotension.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
Sorbitrate (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis, not acute attacks. Sublingual form has faster onset; oral sustained-release provides longer duration. Tolerance develops rapidly with continuous dosing; use a 10-12 hour nitrate-free interval daily. Monitor for hypotension, especially with concurrent PDE-5 inhibitors (e.g., sildenafil) – absolute contraindication due to severe hypotension risk. Headache is common, often transient; advise analgesia. Avoid abrupt discontinuation.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Take exactly as prescribed, do not stop abruptly.,For sublingual tablets: place under tongue and let dissolve; do not swallow.,Avoid alcohol as it can worsen dizziness and hypotension.,Prolonged use may lead to tolerance; a daily nitrate-free period is important.,Store tablets in original glass container away from heat and moisture.,Do not use within 24 hours of erectile dysfunction drugs like Viagra, Cialis, or Levitra.,Common side effects: headache, flushing, dizziness; contact doctor if severe or persistent.,If chest pain persists after one sublingual dose, call 911 immediately.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SORBITRATE vs ISMO, answered by our medical review team.
SORBITRATE is a Nitrate vasodilator that works by Sorbitrate (isosorbide dinitrate) is a nitrate that relaxes vascular smooth muscle by converting to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates coronary arteries and peripheral veins (venodilation > arteriodilation), reducing preload and afterload, thereby decreasing myocardial oxygen demand.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SORBITRATE and ISMO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SORBITRATE is: Sublingual: 2.5-5 mg as needed for acute angina, up to 10 mg per episode. Oral (sustained-release): 40-80 mg twice daily (immediate-release: 10-20 mg three times daily).. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SORBITRATE and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SORBITRATE is classified as Category C. Isosorbide dinitrate (Sorbitrate) has no well-controlled studies in pregnant women. Animal studies have not shown teratogenic effects. Due to vasodilatory effects, there is a poten. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.